Share on LinkedInShare on LinkedIn

ARTICLE · 22 OCTOBER 2007

Intellectual Property News

Intellectual Property News

AustraliaIntellectual Property

Patents

Australia

Interlocutory injunction granted to restrain infringement of a patent
Sanofi-Aventis (Sanofi), a pharmaceutical company, has been successful in obtaining an interlocutory injunction in the Federal Court, restraining another pharmaceutical company, GenRx Pty Ltd, from infringing their patent. Initially, GenRx brought the proceedings and made an application for revocation of Sanofi's patent. Sanofi, the cross-claimant, in turn made an application for an interlocutory injunction restraining GenRx from infringing the patent. While the Court accepted that GenRx is threatening to import and sell products which infringe Sanofi's patent, it also stated that there is a substantial issue to be tried regarding the validity of Sanofi's patent. The Court noted that the long standing exploitation of the patent, and the fact that GenRx failed to bring the revocation proceedings in a timely fashion supported the grant of an injunction. A decision will be made as to whether to

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from